124 related articles for article (PubMed ID: 22646825)
1. Recent developments of transgenic and xenograft mouse models of pancreatic cancer for translational research.
Schütte U; Bisht S; Brossart P; Feldmann G
Expert Opin Drug Discov; 2011 Jan; 6(1):33-48. PubMed ID: 22646825
[TBL] [Abstract][Full Text] [Related]
2. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology.
Mazur PK; Siveke JT
Gut; 2012 Oct; 61(10):1488-500. PubMed ID: 21873467
[TBL] [Abstract][Full Text] [Related]
3. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
4. The mighty mouse: genetically engineered mouse models in cancer drug development.
Sharpless NE; Depinho RA
Nat Rev Drug Discov; 2006 Sep; 5(9):741-54. PubMed ID: 16915232
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise.
Zachos I; Konstantinopoulos PA; Tzortzis V; Gravas S; Karatzas A; Karamouzis MV; Melekos M; Papavassiliou AG
Expert Opin Investig Drugs; 2010 Jul; 19(7):875-87. PubMed ID: 20528482
[TBL] [Abstract][Full Text] [Related]
6. In vitro models of pancreatic cancer for translational oncology research.
Feldmann G; Rauenzahn S; Maitra A
Expert Opin Drug Discov; 2009 Apr; 4(4):429-443. PubMed ID: 20160967
[TBL] [Abstract][Full Text] [Related]
7. Genetically engineered models have advantages over xenografts for preclinical studies.
Becher OJ; Holland EC
Cancer Res; 2006 Apr; 66(7):3355-8, discussion 3358-9. PubMed ID: 16585152
[TBL] [Abstract][Full Text] [Related]
8. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations.
Hruban RH; Adsay NV; Albores-Saavedra J; Anver MR; Biankin AV; Boivin GP; Furth EE; Furukawa T; Klein A; Klimstra DS; Kloppel G; Lauwers GY; Longnecker DS; Luttges J; Maitra A; Offerhaus GJ; Pérez-Gallego L; Redston M; Tuveson DA
Cancer Res; 2006 Jan; 66(1):95-106. PubMed ID: 16397221
[TBL] [Abstract][Full Text] [Related]
9. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches.
Suggitt M; Bibby MC
Clin Cancer Res; 2005 Feb; 11(3):971-81. PubMed ID: 15709162
[TBL] [Abstract][Full Text] [Related]
10. Orthotopic mouse models expressing fluorescent proteins for cancer drug discovery.
Hoffman RM
Expert Opin Drug Discov; 2010 Sep; 5(9):851-66. PubMed ID: 22823260
[TBL] [Abstract][Full Text] [Related]
11. Metastatic thyroid cancer unresponsive to conventional therapies: novel management approaches through translational clinical research.
Sarlis NJ
Curr Drug Targets Immune Endocr Metabol Disord; 2001 Aug; 1(2):103-15. PubMed ID: 12476792
[TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
13. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective.
Singh M; Johnson L
Clin Cancer Res; 2006 Sep; 12(18):5312-28. PubMed ID: 17000664
[TBL] [Abstract][Full Text] [Related]
14. Modeling human osteosarcoma in the mouse: From bedside to bench.
Janeway KA; Walkley CR
Bone; 2010 Nov; 47(5):859-65. PubMed ID: 20696288
[TBL] [Abstract][Full Text] [Related]
15. A historical perspective of pancreatic cancer mouse models.
Colvin EK; Scarlett CJ
Semin Cell Dev Biol; 2014 Mar; 27():96-105. PubMed ID: 24685616
[TBL] [Abstract][Full Text] [Related]
16. Animal models for modeling pancreatic cancer and novel drug discovery.
Bisht S; Feldmann G
Expert Opin Drug Discov; 2019 Feb; 14(2):127-142. PubMed ID: 30657339
[TBL] [Abstract][Full Text] [Related]
17. Targeting Notch signaling in pancreatic cancer.
Ristorcelli E; Lombardo D
Expert Opin Ther Targets; 2010 May; 14(5):541-52. PubMed ID: 20392166
[TBL] [Abstract][Full Text] [Related]
18. Carbonic anhydrase inhibition as a cancer therapy: a review of patent literature, 2007 - 2009.
Poulsen SA
Expert Opin Ther Pat; 2010 Jun; 20(6):795-806. PubMed ID: 20476848
[TBL] [Abstract][Full Text] [Related]
19. What does systems biology mean for biomarker discovery?
Azuaje F
Expert Opin Med Diagn; 2010 Jan; 4(1):1-10. PubMed ID: 23496106
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
